AI-enabled pharma supply chain market seen reaching $2.23 billion by 2030

The Business Research Company says AI use in pharmaceutical supply chains is speeding up drug distribution, inventory control and demand forecasting, with the market projected to nearly double by 2030. Personalized medicines, cold-chain logistics and tighter traceability rules are helping drive demand.

Why it matters: - AI is becoming a core tool for pharma supply chains that need faster decisions, better forecasting and tighter control over temperature-sensitive drugs. - The shift matters because drug makers and distributors are under pressure to deliver medicines more reliably while meeting stricter compliance and traceability demands. - Personalized medicines add complexity to manufacturing and distribution, raising the value of real-time data and predictive planning.

What happened: - The Business Research Company published its Artificial Intelligence (AI) Enabled Pharma Supply Chain Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report says the market will rise from $1.1 billion in 2025 to $1.27 billion in 2026, a 15.5% CAGR. - The report projects the market will reach $2.23 billion by 2030, growing at a 15.1% CAGR. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company made a free sample available here. - The full report is available here.

The details: - AI-enabled pharma supply chains use machine learning, predictive analytics and automation across drug manufacturing, inventory control, distribution and demand forecasting. - The goal is real-time decision-making that improves efficiency, cuts costs and gets medicines to market faster and more reliably. - Earlier market growth was supported by manual operations, fragmented distribution networks, limited digital tracking, paper-based inventory and procurement, and reactive demand planning during health crises. - Future growth is expected to be driven by AI-powered predictive supply chain platforms, wider distribution of biologics and personalized medicines, stricter compliance and traceability standards, expansion of cold-chain logistics and greater use of IoT-based tracking. - The report points to decentralized manufacturing, regional production growth, demand swings during epidemics, handling challenges for biologics and temperature-sensitive drugs, tougher quality assurance and heavier reliance on third-party logistics and outsourcing. - The report says personalized medicines are a key growth driver because AI can better align manufacturing and distribution with patient-specific demand. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

Between the lines: - The market forecast reflects a broader pharma shift from reactive supply chains to data-driven systems that can respond to smaller, more complex and more time-sensitive demand patterns. - Personalized medicine is especially important because it raises the stakes for inventory accuracy, delivery timing and supply chain visibility. - The emphasis on cold chain, traceability and IoT suggests the biggest opportunities are in compliance-heavy segments where delays or temperature errors can be costly.

What's next: - AI adoption is likely to accelerate as pharma companies look for better forecasting, stronger quality control and more resilient logistics. - Growth should be strongest in regions and product categories where regulatory pressure, biologics and temperature-sensitive shipping create the most operational strain. - LinkedIn updates from The Business Research Company may provide additional company announcements and research releases.

The bottom line: - AI-enabled pharma supply chains are moving from a niche efficiency play to a central operating model for a more complex and regulated drug market.